From: What’s new in melanoma? Combination!
Study
PDL1 positive patients (%)
CA209-037 [21]
49
CA209-066 [22]
35
Ca209-067 ipilimumab/nivolumab arm [7]
21.7
Ca209-067 nivolumab monotherapy arm [7]
25.3
Keynote 006 pembro every 2 weeks [23]
80.6
Keynote 006 pembro every 3 weeks [23]
79.8
Keynote 002 [24]
69
Keynote 001 [25]
77
